| 1. |
李艾青, 龔雪, 林靜芳, 等. 自身免疫性癲癇研究新進展. 中國神經精神疾病雜志, 2019, 45(8): 502-505.
|
| 2. |
Levite M. Autoimmune epilepsy. Nature Immunology, 2002, 3(6): 500.
|
| 3. |
Ong M, Kohane I, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurology, 2014, 71(5): 569-574.
|
| 4. |
Scheffer I, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(4): 512-521.
|
| 5. |
Graus F, Titulaer M, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology, 2016, 15(4): 391-404.
|
| 6. |
Geis C, Planagumà J, Carre?o M, et al. Autoimmune seizures and epilepsy. The Journal of Clinical Investigation, 2019, 129(3): 926-940.
|
| 7. |
Liu X, Yan B, Wang R, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia, 2017, 58(12): 2104-2111.
|
| 8. |
Lin J, Li C, Li A, et al. Encephalitis with antibodies against the GABA receptor: high mortality and risk factors. Frontiers in Neurology, 2019, 10: 1030.
|
| 9. |
Steriade C, Britton J, Dale R, et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia, 2020, 61(7): 1341-1351.
|
| 10. |
余年, 狄晴. 正確認識自身免疫性癲癇與自身免疫性腦炎的關系. 中華神經科雜志, 2020, 53(2): 152-156.
|
| 11. |
Hong Z, Qu B, Wu X, et al. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Epilepsia, 2009, 50(10): 2192-2198.
|
| 12. |
Bien C, Bauer J, Deckwerth T, et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in rasmussen's encephalitis. Annals of Neurology, 2002, 51(3): 311-318.
|
| 13. |
Carre?o M, Bien C, Asadi-Pooya A, et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Research, 2017, 129: 101-105.
|
| 14. |
Fisher R, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014, 55(4): 475-482.
|
| 15. |
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiological Reviews, 2017, 97(2): 839-887.
|
| 16. |
Bien C, Vincent A, Barnett M, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain, 2012, 135: 1622-1638.
|
| 17. |
Malter MP, Frisch C, Zeitler H, et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure, 2015, 30: 57-63.
|
| 18. |
Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain A Journal of Neurology, 2004, 127: 1831-1844.
|
| 19. |
Varadkar S, Bien C, Kruse C, et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. The Lancet Neurology, 2014, 13(2): 195-205.
|
| 20. |
Dubey D, Farzal Z, Hays R, et al. Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis. Therapeutic Advances in Neurological Disorders, 2016, 9(5): 369-377.
|
| 21. |
Titulaer M, Mc Cracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology, 2013, 12(2): 157-165.
|
1/5
WeChat